Eagle Health Investments LP Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK

Eagle Health Investments LP grew its stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 36.0% in the 1st quarter, HoldingsChannel reports. The fund owned 494,019 shares of the company’s stock after purchasing an additional 130,719 shares during the quarter. Scholar Rock makes up 4.2% of Eagle Health Investments LP’s investment portfolio, making the stock its 7th largest position. Eagle Health Investments LP’s holdings in Scholar Rock were worth $24,286,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in SRRK. AQR Capital Management LLC increased its stake in shares of Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Scholar Rock by 12.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after purchasing an additional 5,831 shares during the period. Millennium Management LLC grew its holdings in Scholar Rock by 37.4% in the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after buying an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Scholar Rock by 25.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after buying an additional 34,594 shares in the last quarter. Finally, Strs Ohio bought a new position in Scholar Rock during the 1st quarter worth $77,000. Institutional investors own 91.08% of the company’s stock.

Insiders Place Their Bets

In related news, Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the transaction, the director owned 59,511 shares of the company’s stock, valued at $3,205,857.57. The trade was a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joshua Reed sold 3,053 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the sale, the director directly owned 19,518 shares of the company’s stock, valued at $1,048,897.32. This represents a 13.53% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock valued at $923,108 over the last 90 days. 10.30% of the stock is owned by company insiders.

Scholar Rock Price Performance

Scholar Rock stock opened at $48.93 on Tuesday. The firm has a market cap of $5.86 billion, a PE ratio of -13.63 and a beta of 0.67. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. The stock’s fifty day moving average price is $50.05 and its two-hundred day moving average price is $47.56. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $58.49.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the previous year, the company posted ($0.67) earnings per share. As a group, research analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Wedbush restated an “outperform” rating and issued a $58.00 price target on shares of Scholar Rock in a research note on Tuesday, July 21st. HC Wainwright raised their price target on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Barclays lifted their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).